Prospective Follow-up of a Multicentric Cohort of Children With Prenatal Discovery of Mild Isolated Cerebral Ventriculomegaly. Evaluation at 2 and 5 Years.

NCT ID: NCT00421772

Last Updated: 2007-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

245 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-01-31

Study Completion Date

2007-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Isolated uni or bilateral mild cerebral ventriculomegaly represents the most frequent "minor" cerebral anomalies discovered by antenatal echography. There are not French data making it possible to specify the incidence and the prevalence of this pathology and international data of the prevalence are very heterogeneous, going, according to the published series, of 1.48 to 22 per 1000 births.

The prognostic of ventriculomegaly remains dubious : the studies have small populations, are for the majority retrospectives with a short and often vague follow-up. The announced rate of after-effects varies between 0 and 48 %.

The objective of this study is to evaluate the neuropsychological development until the 5 years age of the children for whom a prenatally diagnosis of mild isolated ventriculomegaly was carried (absence of another cerebral or extra-cerebral anomaly in imagery and a negative aetiology). This prospective cohort will be compared with children for whom no neurological anomaly was prenatally detected.

The children diagnosed for an mild isolated cerebral ventriculomegaly will be identified by the investigators among medical files of the Centers of Prenatal Diagnosis (CPDPN) of the UH of Angers and the UH of Nantes. The patient inclusion will be done at the 2 years age after parental agreement, with a follow-up at 5 years. The control children will be included under the same conditions after having ensured of the normality of the echographies of 22 and 30 gestational weeks. The follow-up of these 2 cohorts will be based on the 2 years obligatory paediatric examination, and on the network "Naitre ensemble" set up in the Pays de la Loire Loire. In addition to the clinical routine examinations, standardized neuropsychological examinations will be done (Brunet Lezine Revised score at 2 years, NEPSY at 5 years and ASQ at 2 and 5 years).

This study will allow to compare the neuropsychological development at school age of the children diagnosed for a foetal mild, apparently isolated, cerebral ventriculomegaly from children not presenting any foetal anomaly, to evaluate the incidence of the mild isolated ventriculomegaly, to identify the predictive factors of the neuropsychological anomalies in the children diagnosed for ventriculomegaly and to compare (in the children diagnosed for ventriculomegaly), the neuropsychological development at the school age of the children having a ventricular atrium between 10 and 12 mm with those having a ventricular atrium between 12,1 and 15 mm.

This study will allow to define the neuropsychological morbidity of the foetal mild isolated cerebral ventriculomegaly and will allow to define the best clinical and educational follow up of these children and their family.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Ventriculomegaly

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

DEFINED_POPULATION

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Diagnosis of foetal mild isolated cerebral ventriculomegaly at 32 gestational weeks by the Centers of Prenatal Diagnosis (CPDPN) of the UH of Angers and the UH of Nantes
* Age : 22 to 26 months


* Written informed consent
* Negative diagnostic of foetal cerebral ventriculomegaly at the prenatal echography made at 22 gestational weeks
* Age : 22 to 26 months


* Preterm birth (\< 37 weeks of gestation)
* APGAR ≤ 3 at 5 minutes after birth
* Serious prenatal pathology with neurologic aspect requing intensive care
* postnatal hydrocephalus
* Diagnostic of a eurological pathology at birth
* Diagnostic d'une pathologie neurologique associée à la naissance


* Preterm birth (\< 37 weeks of gestation)
* APGAR ≤ 3 at 5 minutes after birth
* Serious prenatal pathology with neurologic aspect requing intensive care
* postnatal hydrocephalus
* Diagnostic of a neurological pathology at birth
* Cerebral or extracerebral anomaly at the prenatal echographies
* Chromosomal anomaly discovered after birth
Minimum Eligible Age

22 Months

Maximum Eligible Age

26 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ministry of Health, France

OTHER_GOV

Sponsor Role collaborator

University Hospital, Angers

OTHER_GOV

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Claude BOUDERLIQUE, MD

Role: PRINCIPAL_INVESTIGATOR

UH of Angers

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UH of Angers

Angers, , France

Site Status RECRUITING

UH of Nantes

Nantes, , France

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Claude BOUDERLIQUE, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Claude BOUDERLIQUE, MD

Role: primary

Norbert WINER, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DGS : 2006/0432

Identifier Type: -

Identifier Source: secondary_id

CCPPRB : 2006/08

Identifier Type: -

Identifier Source: secondary_id

PHRC-05-03

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

LUMIERE on the FETUS
NCT04142606 RECRUITING
Brain Ultrafast Ultrasound Imaging
NCT07299721 NOT_YET_RECRUITING